Emile LORIA (MD)

Chairman of the Board

Dr. Loria was a researcher in the cancer institute in Villejuif and after in the cancer and immunogenetics institute (INSERM-CNRS). In 1986, he founded MS Medical Synergy, a company specializing in drug development and management. He was Chairman and CEO of Biovector Therapeutics. Emile also founded OSE Immunotherapeutics. He has decades of experience in the life sciences industry and in the past held management positions at Ciba-Geigy and Sanofi.

Gerard Tobelem


Board member

Dr. Tobelem was hematology professor at Paris 7 University and former head of Paris’ Lariboisière hospital blood disorders’ department. He was also executive chairman of the « french blood institution ». He previously held roles in the French Ministry of Research and advised several pharmaceutical companies in relation to their R&D programs’ strategies.

Philippe Lefebvre

Philippe LEFEBVRE (MD, PhD)

Board member

Prof. Lefebvre graduated from the University of Liège (ULg) in 1987 and earned his title as Doctor of Biomedical Science in 1991 after writing a paper on the neurobiology of the inner ear. That same year, he also obtained recognition as otolaryngology specialist. He completed a postdoctoral fellowship at the Albert Einstein College of Medicine in New York where he pursued his research on the neurobiology of the inner ear. In the US, he also acquired advanced skills in ear surgery. In 1997, he was appointed clinical professor at ULg. Since 2002, he is Professor of ENT at ULg and head of the ENT department. Prof. Lefebvre gained throughout his career a strong reputation in neurobiology of the inner ear and in pathophysiology of deafness.

Stephane Silvente


Board member

Stephane is an entrepreneur with 30+ years’ experience in building and managing dynamic teams. Stephane previously developed innovative technology in the Food Tech industry, generating several patents which were sold to Switzerland-based Nestlé. Afterwards Stephane founded Affichem, a France-based biotech company developing early-stage drug candidates in oncology, neurology and dermo-cosmetics. Stephane obtained a DESS degree from the University of Valenciennes, is also graduated from the EDC Business School in Paris and holds MBA from the Toulouse Business School.



Board member

Graduating as doctor in veterinary medicine from the University of Liège, Hugues pursued a PhD in immunology at the GIGA. He then acquired a broad experience in the medical field ranging from R&D to commercialization of innovative vaccines and diagnostic applications during his 10 years’ experience at GSK and Unisensor. Hugues is an Investment Manager at Noshaq.